AMOYTOP(SH:688278) Xin Lang Cai Jing·2025-08-21 13:12Core Viewpoint - The company has received approval from the National Medical Products Administration for a new indication of its product Yipeisheng (generic name: Yipei Growth Hormone Injection) for "Adult Growth Hormone Deficiency (AGHD)" [1] Group 1: Product Development - Yipeisheng is a long-acting growth hormone developed by the company, utilizing 40kD Y-type branched polyethylene glycol for single-molecule modification [1] - The product is classified as a Class 1 new drug for therapeutic biological products [1] Group 2: Market Approval - The existing indication for Yipeisheng, which is "for the treatment of growth retardation due to growth hormone deficiency in children aged 3 years and older," was approved for market launch in May 2025 [1] - The newly approved clinical trial application expands the indication to include "Adult Growth Hormone Deficiency (AGHD)" [1]